[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasolabial-fold-wrinkles\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasolabial-fold-wrinkles":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634922","cellujuve-for-the-treatment-of-moderate-to-severe-nlfs-100634922",false,"NCT07545980","CelluJuve® for the Treatment of Moderate to Severe NLFs","Open-Label Proof-of-Concept Study of CelluJuve® for the Treatment of Moderate to Severe Nasolabial Folds","Inclusion Criteria\n\n1. Male or female of any race, 22 years of age or older, who are seeking therapy for correction of moderate to severe NLFs. Female subjects of childbearing potential must have a negative UPT at Visit 1 and practice a reliable method of contraception throughout the study.\n2. Moderate to severe bilateral NLFs with a severity grading of 3 or 4 as per the Wrinkle Severity Rating Scale (WSRS). Each NLF must have the same WSRS grade.\n3. Healthy skin in the study treatment area and free of conditions or diseases that could interfere with study evaluations.\n4. Able to follow study instructions and complete all required visits.\n5. Signed ICF, Photographic Release, HIPAA, and if applicable the California Experimental Research Subject's Bill of Rights.\n\nExclusion Criteria\n\n1. Female subjects that are pregnant, breast-feeding, or of childbearing potential and not practicing reliable contraception.\n2. A condition or situation that puts the subject at significant risk, may confound the study results, or may significantly interfere with subjects' study participation.\n3. Study staff or close relative to study staff (e.g., parents, children, siblings, or spouse).\n4. Abnormal visual tests (i.e., Snellen acuity test worse than 20\u002F40 with corrections, if applicable), abnormal confrontational visual field test, and\u002For abnormal ocular motility test.\n5. Subjects with known prolonged bleeding times due to disease or anticoagulants (e.g., warfarin). If on a drug or supplement that prolongs bleeding times (e.g., non-steroidal anti-inflammatory, anticoagulant, high-dose vitamin E, fish oil, corticosteroids), wait 7 days or until bleeding times return to normal before injecting. (Note: low dose 81mg\u002Fday ASA is permitted).\n6. Acute or chronic skin disease, inflammation, or related conditions, cancerous or precancerous lesions near the treatment area.\n7. Presence of any skin pathology or condition that could interfere with the evaluation of the treatment areas, worsen due to study treatment, or require interfering topical, systemic or surgical therapy.\n8. Herpes simplex lesion flare-ups greater than 6 per year.\n9. Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with interpretation of study results or compliance of the subject and could make the subject inappropriate for study entry.\n10. Known history of allergic\u002Fanaphylactic reactions to any of the components of CelluJuve® including known sensitivity to cellulose or local anesthetics of the amide type, history of multiple severe allergies, or history of anaphylactic shock.\n11. Malignancy (excluding non-melanoma skin cancer) within the past 3 years.\n12. History of systemic granulomatous diseases active or inactive (e.g., Sarcoid, Wegener's disease, TB, etc.) or connective tissue diseases (e.g., lupus, dermatomyositis, etc.).\n13. History or evidence of keloid scarring, susceptibility to keloid formation or hypertrophic scarring, or delayed healing activity.\n14. History or presence of severe chronic systemic diseases, including but not limited to, poorly controlled diabetes mellitus (all types), congestive heart failure, severe liver disease, severe kidney disease, and others as judged by the Investigator.\n15. History or presence of any autoimmune or connective tissue disease, receiving treatment with immunomodulating therapy, or is immunocompromised or immunosuppressed.\n16. Known history of clinically significant skin pigmentation disorders.\n17. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.\n18. Elective, clinically significant facial procedures that may confound the interpretation of the results in the NLF area (PI discretion), prior to study enrollment.\n19. Physical attribute that may interfere with NLF assessment or treatment (e.g., facial hair, acne scarring, etc.).\n20. Received a COVID-19 vaccine within 2 weeks of study entry.\n21. Undergoing, or planning to undergo, radiation or ultrasound therapy in the treatment area.\n22. History of any previous injectable filler to the study treatment area.\n23. Exposure to any other investigational drug\u002Fdevice within 90 days of study entry or planning to participate in another investigation during the course of the study.","ALL","22 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"NA","Single-center, open-label proof of concept study assessing the safety and effectiveness of CelluJuve® for the treatment of moderate to severe NLFs",[26],"Nasolabial Fold Wrinkles",[28],"Nasolabial Folds","RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2026-04-29",{"date":37,"type":20},"2028-07-31",{"name":39,"class":40},"Spiderwort Biotechnologies Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100451732","phase-1-bc-101-in-treatment-of-nasolabial-fold-wrinkles-100451732","NCT05162326","BC-101 in Treatment of Nasolabial Fold Wrinkles","A Phase 1\u002F2 Study of the Safety and Efficacy of BC-101 in Treatment of Nasolabial Fold Wrinkles Via Subcutaneous\u002FIntradermal Injection","Inclusion Criteria:\n\n1. Subjects who are in general good health condition.\n2. Subjects who have moderate to extremely deep bilateral nasolabial fold wrinkles, as documented by a score of 3 or greater on the six-point Evaluator Wrinkle Severity Assessment scale (0-5).\n3. Subjects who are dissatisfied with both nasolabial fold wrinkles based on a score of -1 or -2 on the Subject Wrinkle Assessment Scale (-2 to +2).\n4. Subjects who voluntarily adhere to the research procedures and ensure good compliance during the research period.\n5. Subjects who fully understand the research nature of this study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Subjects who have an active cutaneous infection on the face.\n2. Subjects with existing malignant neoplasm.\n3. Subjects with persistent pre-cancerous lesions (e.g., actinic keratosis).\n4. Subjects who have active dermal diseases, inflammation, or any related disease.\n5. Subjects who have cosmetic or surgical treatment on nasolabial fold area in 3 months before the study (including laser, chemical peels, fillers, botulinum toxin).\n6. Subjects who are pregnant, breastfeeding, or whose urinary pregnancy test is positive before participation in the study.\n7. Subjects who are allergic to low-molecular-weight heparin sodium or human albumin.","40 Years","80 Years",{"count":52,"type":20},9,[54],"PHASE1","This is an open-label, single-arm, dose-escalating study to evaluate the safety and tolerability of BC-101 administered via subcutaneous\u002Fintradermal injection in the treatment of moderate to severe nasolabial folds.",[26],"NOT_YET_RECRUITING","2025-12-21",{"date":60,"type":33},"2025-12-29",{"date":62,"type":20},"2026-12-01",{"date":64,"type":20},"2028-02-20",{"name":66,"class":40},"Bright Cell, Inc.",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100612567","evaluation-of-facial-ha-dermal-fillers-in-real-life-conditions-100612567","NCT07255261","Evaluation of Facial HA Dermal Fillers in Real-Life Conditions","Post-Marketing Clinical Follow Up On Hyaluronic Acid-Based Dermal Fillers Using COLD-X™ Technology By Symatese","Inclusion Criteria:\n\n* Subject seeking an aesthetic correction of the infraorbital hollows with FASY P and\u002F or an aesthetic correction of the lips with ESTYME® LIPS, and\u002F or an aesthetic correction of the perioral lines with ESTYME® SMOOTH, and\u002F or an aesthetic correction of nasolabial folds with ESTYME® SMOOTH, and\u002F or an aesthetic correction of cheeks with ESTYME® SCULPT.\n* Subject who agreed to participate and have signed an informed consent.\n* Age: over 18 years old.\n* Subject being affiliated to a health social security system.\n\nExclusion Criteria:\n\n* Minors\n* Subjects with a known allergy to hyaluronic acid, lidocaine or amide local anesthetics.\n* Subjects with porphyria.\n* Subjects with an autoimmune disorder, or using an immunosuppressant medication.\n* Pregnant or breastfeeding women.\n* Subjects with inflammation, infection or cutaneous disorders, at the treatment site or nearby.\n* Subjects with bleeding disorders or in subjects receiving thrombolytic or anticoagulant treatment.\n* Areas other than those recommended by the IFU.\n* Subject deprived of liberty by judicial or administrative decision.\n* Adults under a legal protection measure (guardianship\u002Fcuratorship).\n* Subject under legal protection order.",true,"18 Years",{"count":77,"type":20},460,[23],"The goal of this post-market interventional study is to confirm, under real-life conditions, the safety and performance of hyaluronic acid-based dermal fillers intended to modify skin anatomy and facial appearance. Subjects aged 18 years or older seeking aesthetic treatment of the lips, perioral lines, nasolabial folds, cheeks, and\u002For infraorbital hollows may be included. The main question the study aims to answer is: How long does the effect of the products last?\n\nParticipants will attend follow-up visits every 6 months after the initial injection, until the end of follow-up at 24 months. During each visit, the investigator will assess performance and safety through a simple clinical examination. At each follow-up visit, subjects will also evaluate the aesthetic improvement compared with their pre-injection appearance. Subjects will be asked about the level of pain experienced during the initial injection.\n\nIf the subject wishes, a retreatment may be performed at the 12-month or 18-month follow-up visit, provided that the treated area(s) have returned to the pre-injection state.",[81,82,26,83,84],"Lips Enhancement","Perioral Wrinkles","Cheek Augmentation","Infraorbital Hollows","2025-12-01",{"date":87,"type":33},"2025-12-08",{"date":89,"type":33},"2025-07-02",{"date":91,"type":20},"2028-07",{"name":93,"class":40},"Symatese",8]